Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines

Full text
Author(s):
Show less -
Lobo, Yara A. [1] ; Bonazza, Camila [2] ; Batista, Fabricio P. [1] ; Castro, Rodrigo A. [2] ; Bonturi, Camila R. [1] ; Salu, Bruno R. [1] ; Sinigaglia, Rita de Cassia [3] ; Toma, Leny [1] ; Vicente, Carolina M. [1] ; Pidde, Giselle [4] ; Tambourgi, V, Denise ; Alvarez-Flores, Miryam P. [5] ; Chudzinski-Tavassi, Ana M. [5] ; Oliva, V, Maria Luiza
Total Authors: 14
Affiliation:
[1] V, Univ Fed Sao Paulo, Biochem, BR-04044020 Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Gynecol, BR-04044020 Sao Paulo, SP - Brazil
[3] Univ Fed Sao Paulo, Electron Microscopy Ctr, BR-04044020 Sao Paulo, SP - Brazil
[4] V, Inst Butantan, Immunochem, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP - Brazil
[5] Inst Butantan, Ctr Excellence New Target Discovery CENTD, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Cancer Letters; v. 491, p. 108-120, OCT 28 2020.
Web of Science Citations: 0
Abstract

Breast cancer is the most common malignant tumor among women worldwide, and triple-negative breast cancer is the most aggressive type of breast cancer, which does not respond to hormonal therapies. The protease inhibitor, EcTI, extracted from seeds of Enterolobium contortisiliquum, acts on the main signaling pathways of the MDA-MB-231 triple-negative breast cancer cells. This inhibitor, when bound to collagen I of the extracellular matrix, triggers a series of pathways capable of decreasing the viability, adhesion, migration, and invasion of these cells. This inhibitor can interfere in the cell cycle process through the main signaling pathways such as the adhesion, Integrin/FAK/SRC, Akt, ERK, and the cell death pathway BAX and BCL-2. It also acts by reducing the main inflammatory cytokines such as TGF-alpha, IL-6, IL-8, and MCP-1, besides NF kappa B, a transcription factor, responsible for the aggressive and metastatic characteristics of this type of tumor. Thus, the inhibitor was able to reduce the main processes of carcinogenesis of this type of cancer. (AU)

FAPESP's process: 17/06630-7 - Fragments derived from the structure of protease inhibitors with selectivity for inhibition of mammalian and microorganism enzymes and its role as an anti-inflammatory, antimicrobial, antithrombotic and anti- tumor agent: mechanism of action
Grantee:Maria Luiza Vilela Oliva
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 17/07972-9 - Development of lead agents for prophylaxis and treatment of cardiovascular diseases
Grantee:Maria Luiza Vilela Oliva
Support Opportunities: Regular Research Grants